AnorMED to present at the Orion Healthcare Conference
20 Junio 2006 - 4:30PM
PR Newswire (US)
VANCOUVER, June 20 /PRNewswire-FirstCall/ -- AnorMED Inc.
(AMEX:AOM; TSX:AOM) today announced that William J. Adams, Chief
Financial Officer will present at the Orion 11th Annual Healthcare
Conference being held in Mt. Tremblant, Quebec, on Wednesday, June
21 at 8:00am EDT. About AnorMED Inc. AnorMED is a chemistry-based
biopharmaceutical company focused on the discovery, development and
commercialization of new therapeutic products in the areas of
hematology, oncology and HIV, based on the Company's research into
chemokine receptors. The Company's product pipeline includes
MOZOBIL, currently in Phase III studies in cancer patients
undergoing stem cell transplants; AMD070, currently in Phase I/II
studies in HIV patients; and several novel classes of compounds in
preclinical development that target specific chemokine receptors
known to be involved in a variety of diseases. Additional
information on AnorMED Inc. is available on the Company's website
http://www.anormed.com/. Note: Certain of the statements contained
in this press release may contain forward-looking statements and
forward-looking information within the meaning of the Private
Securities Litigation Reform Act of 1995 or applicable Canadian
securities laws. Statements or information regarding our strategy,
future operations, future financial position, timing and completion
of clinical trials, prospects and plans and objectives of
management are forward- looking statements. The words "anticipates,
"believes", "budgets", "could", "estimates", "expects,"
"forecasts", "intends", "may", "plans", "projects", "schedule",
"should", "will", "would" and similar expressions are intended to
identify forward-looking statements or information, although not
all forward- looking statements or information contain these
identifying words. Plans, intentions or expectations disclosed in
any forward-looking statements or information should not be read as
guarantees of future results or events, and will not necessarily be
accurate indications of whether or the times at or by which such
results or events will be achieved. Forward-looking statements or
information involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of the Company, or industry results, to be materially
different from any future results, performance or achievements
expressed or implied by such forward- looking statements or
information including: we may not be able to develop and obtain
regulatory approval for MOZOBIL in stem cell transplant indications
and any future product candidates in our targeted indications; we
may not be able to establish marketing and sales capabilities and
the costs of launching MOZOBIL stem cell transplant indications and
any future products in our targeted indications may be greater than
anticipated; we rely on third parties for the continued supply and
manufacture of MOZOBIL, we may face unknown risks related to
intellectual property matters; we may face competition from other
pharmaceutical or biotechnology companies. Investors are referred
to the discussion of such risks, uncertainties and other factors in
AnorMED's Final Short Form Prospectus dated December 1, 2005 filed
on SEDAR with Canadian securities regulatory authorities and in
Exhibit 99.1 to AnorMED's Report on Form 6-K filed with the U.S.
Securities and Exchange Commission on December 23, 2005.
Forward-looking statements or information are based on the beliefs,
opinions and expectations of the Company's management at the time
they are made, and the Company does not assume any obligation to
update its forward- looking statement or information if those
beliefs, opinions or expectations change, or there is new
information or other circumstances should change other than as
required by applicable law. For further information: W.J. (Bill)
Adams, CA Kim Nelson, Ph.D. Chief Financial Officer Manager,
Investor Relations Tel: 604-530-1057 Tel: 604-532-4654 Email: Cell:
604-614-2886 Email: DATASOURCE: AnorMED Inc. CONTACT: W.J. (Bill)
Adams, CA, Chief Financial Officer, Tel: (604) 530-1057, Email: ;
Kim Nelson, Ph.D., Manager, Investor Relations, Tel: (604)
532-4654, Cell: (604) 614-2886, Email:
Copyright